Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD

NCT00421122 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00421122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00421122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
November 30, 2007
Enrollment
315 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease